Effect of sarpogrelate hydrochloride on platelet-derived microparticles and various soluble adhesion molecules in diabetes mellitus.
We measured platelet-derived microparticles, activated platelets, and various adhesion molecules in 48 patients with diabetes mellitus. We also performed a comparative study of these parameters before and after administration of sarpogrelate hydrochloride. The numbers of platelet-derived microparticles and activated platelets were increased significantly in diabetic patients, and CD63-positive platelets were increased in patients with diabetic complications and poorly controlled blood glucose. Soluble adhesion molecules and thrombomodulin were also increased significantly. After administration of sarpogrelate hydrochloride, not only CD62p- and CD63-positive platelets, but also platelet-derived microparticles were decreased significantly. Soluble adhesion molecules and thrombomodulin were also significantly decreased after the treatment. These data suggest that (a) in patients with diabetes, antiplatelet therapy with sarpogrelate hydrochloride is a useful antithrombin therapy because it suppresses the production of intrinsic coagulants by activated platelets; and (b) sarpogrelate hydrochloride decreases endothelial cell damage via adhesion molecules.
Shouzu
A
A
The Second Department of Internal Medicine, Kansai Medical University, Moriguchi, Osaka, Japan.
Nomura
S
S
Hayakawa
T
T
Omoto
S
S
Shimizu
H
H
Miyake
Y
Y
Yonemoto
T
T
Fukuhara
S
S
Iwasaka
T
T
Nishikawa
M
M
Inada
M
M
D015703:Antigens, CD / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects*; D015815:Cell Adhesion Molecules / Q000097:blood* / Q000187:drug effects; D003920:Diabetes Mellitus / Q000097:blood* / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000453:epidemiology; D003929:Diabetic Neuropathies / Q000097:blood; D003930:Diabetic Retinopathy / Q000097:blood; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D015539:Platelet Activation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D010980:Platelet Membrane Glycoproteins / Q000187:drug effects; D011507:Proteinuria; D012016:Reference Values; D013386:Succinates / Q000494:pharmacology*; D060149:Tetraspanin 30; D019010:Vascular Cell Adhesion Molecule-1 / Q000097:blood
D015703:Antigens, CD; D015815:Cell Adhesion Molecules; D006442:Glycated Hemoglobin; D018799:Intercellular Adhesion Molecule-1; D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins; D013386:Succinates; D060149:Tetraspanin 30; D019010:Vascular Cell Adhesion Molecule-1; C554586:CD63 protein, human; C064294:sarpogrelate